Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut Cancerologie de l'Ouest
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Adenocarcinoma of the prostate metastatic Age\> 18 years3.
Life expectancy\> 12 months;
Performance Index status \<3 PSA ≥ 4 ng / ml Zoledronic acid treatment in progress as recommended by the Authority for the Marketing Creatinine clearance above 30 ml / min Lack of maintenance causing disabling pain not lying down long (30 minutes) No history of radiotherapy to the region to be irradiated Absence of neurological signs compression Distance between the metastasis and spinal cord ≥ 5 mm Absence of metastases unstable metastatic epidural spinal cord compression or may require surgery before radiotherapy
You may not be if
Concomitant treatment with a drug testing, participation in another clinical trial within \<30 days
Presence of central system nervous desease (symptoms or progressive), Patient with a severe neurological disease, current manifestations of peripheral neuropathy\> grade 2 NCI-CTC V4 Existence of another severe pulmonary disease, liver or kidney, digestive likely to be exacerbated by treatment,
Untreated with zoledronic acid
Treatment with a bisphosphonate other than Zoledronic acid
Clinically significant hypersensitivity to zoledronic acid, other bisphosphonates or to any excipients in the formulation of Zometa.
Creatinine clearance below 30 ml / min
History of another primary cancer (except basal cell skin cancer)
Or demented patient with altered mental status who can not obtain informed consent. / Persons deprived of liberty or under guardianship
Pain not resulting in maintaining the prolonged supine position (30 minutes)
PSA below 4 ng / ml
History of radiotherapy in localized tumor site
Distance between the metastasis and spinal cord \<5 mm
Monitoring impossible because of psychological, sociological or because of geographical distance.
